|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 12/02/16 Shire plc 8-K:1,9 12/02/16 6:184K Davis Polk & … LLP 01/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 17K 2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 43K 3: EX-99.1 Miscellaneous Exhibit HTML 13K 4: EX-99.2 Miscellaneous Exhibit HTML 19K 5: EX-99.3 Miscellaneous Exhibit HTML 12K 6: EX-99.4 Miscellaneous Exhibit HTML 18K
Exhibit 99.2
 |
5 The North Colonnade Canary Wharf London E14 4BB United Kingdom Tel +44 (0)20 7623 2323 barclays.com
|
PRIVATE AND CONFIDENTIAL
Shire plc (the “Company”)
5 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
For the attention of: Thomas Greene
21 November 2016
SHIRE PLC – CONSENT REQUEST
| 1. | We refer to: |
| (A) | the US$2,100,000,000 revolving credit facilities agreement dated 12 December 2014 (as amended on 25 November 2015) between, among others, Shire plc as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent (the “Facilities Agreement”); and |
| (B) | your letter to us dated 8 November 2016 in which you requested that the Majority Lenders consent to certain amendments to schedule 9 (Existing Security), to schedule 10 (Existing Loans) and to schedule 11 (Existing Financial Indebtedness) of the Facilities Agreement (the “Consent Request”). |
| 2. | Unless otherwise defined, terms and expressions defined in the Facilities Agreement or in the Consent Request shall have the same meanings when used in this letter and references to Clauses in this letter are references to the relevant clauses of the Facilities Agreement. |
| 3. | We confirm that we have received the consent of the Majority Lenders to the Requested Amendments and consequently that the Requested Amendments shall, provided that you and the other Obligor sign, date and return to us a copy of this letter in accordance with paragraph 1.3 of the Consent Request become effective immediately and automatically, and from that date the Facilities Agreement and the Consent Request shall be read and construed as one document. |
| 4. | Please confirm your agreement to the terms of this letter by signing, dating and returning a copy thereof. |
| 5. | This letter may be executed in any number of counterparts and this has the same effect as if the signatures on the counterparts were on a single copy of this letter. |
| 6. | This letter is a Finance Document. |
Barclays Bank PLC Authorised by the Prudential Regulation Authority and regulated by the financial Conduct Authority and the Prudential Regulation Authority.
Registered in England. Registered No. 1026167. Registered office: 1 Churchill Place. London E14 SHP
| 7. | The provisions of Clause 46 (Governing law) and Clause 47 (Enforcement) are incorporated into this letter as though they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter. |
Yours faithfully
/s/ Nick Williams
……………………………
for and on behalf of
Barclays Bank PLC
as Facility Agent, for itself and on behalf of each of the Finance Parties
Acknowledged and agreed
/s/ Jeffrey Poulton
……………………………
for and on behalf of
Shire plc
/s/ Michael Garry
……………………………
for and on behalf of
Shire Acquisitions Investments Ireland DAC
Date: 1 December 2016
APPENDIX 2
SCHEDULE 9
EXISTING SECURITY
| Name of member of the Group |
Security | Total Principal Amount of Indebtedness Secured |
|
Pharma International Insurance
|
Collateral against letters of credit |
US$ 15,000,000
|
| NPS Pharmaceuticals, Inc. | Security interest in certain patents and intellectual property
|
US$ 81,350,000 |
aPPENDIX 3
Schedule
10
Existing Loans
| Name of member of the Group |
Loan | Total Principal Amount s |
| Shire Human Genetic Therapies, Inc | Supplier loan |
EUR7,500,000
|
|
Shire Pharmaceutical Holdings Ireland Limited
|
Supplier loan | EUR12,000,000 |
APPENDIX 4
Schedule
11
Existing Financial Indebtedness
| Name of member of the Group |
Financial Indebtedness | Total Principal Amount s |
|
Pharma International Insurance
|
Counter indemnity obligations related to bank issued letters of credit |
US$ 15,000,000
|
| Shire |
Counter indemnity obligations related to bank issued guarantees
|
Up to EUR 90,000,000
|
| Shire HGT Inc. | US property capital lease |
US$ 7,737,000
|
| Shire ViroPharma Incorporated | US property capital lease | US$ 5,255,000
|
| NPS Pharmaceuticals, Inc. | Secured non-recourse debt | US$ 81,350,000
|
| Multiple Subsidiaries of the Company | Uncommitted overdraft and money market lines to the extent drawn
|
Up to US$185,000,000
|
| Multiple Subsidiaries of Baxalta Incorporated | Property capital leases
|
US$ 335,500,000 |